$9.50 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Equities research analysts forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will post $9.50 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The lowest sales estimate is $8.72 million and the highest is $10.10 million. Conatus Pharmaceuticals reported sales of $800,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 1,087.5%. The business is expected to report its next earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $9.50 million for the current financial year, with estimates ranging from $35.29 million to $36.70 million. For the next year, analysts anticipate that the firm will report sales of $56.28 million per share, with estimates ranging from $39.50 million to $116.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Conatus Pharmaceuticals.

Several research firms have recently issued reports on CNAT. Roth Capital began coverage on shares of Conatus Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $20.00 price target for the company. S&P Equity Research raised their price target on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th. Zacks Investment Research downgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $13.67.

Hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC bought a new position in shares of Conatus Pharmaceuticals during the second quarter valued at $101,000. Wells Fargo & Company MN raised its stake in Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after buying an additional 18,588 shares during the last quarter. New York State Common Retirement Fund raised its stake in Conatus Pharmaceuticals by 156.4% during the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after buying an additional 14,700 shares during the last quarter. Rhumbline Advisers bought a new position in Conatus Pharmaceuticals during the second quarter worth $156,000. Finally, OxFORD Asset Management LLP bought a new position in Conatus Pharmaceuticals during the second quarter worth $230,000. 38.77% of the stock is owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals (CNAT) opened at $5.14 on Wednesday. Conatus Pharmaceuticals has a 52 week low of $3.88 and a 52 week high of $9.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69.

WARNING: “$9.50 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/9-50-million-in-sales-expected-for-conatus-pharmaceuticals-inc-cnat-this-quarter.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply